The EPIC-B trial demonstrates the efficacy of cemiplimab monotherapy as a treatment for locally advanced or metastatic penile cancer (la/mPC). The trial met its primary endpoint, with a clinical ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877 ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

India - Mice Not Meek Over Morality And Amendment. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...